DOSE OF REALITY: LAWMAKERS MUST HOLD BIG PHARMA ACCOUNTABLE IN SENATE FINANCE HEARING

03-14-2022 Blog Posts

Congress Can Refocus Attention on Market-Based Solutions to Crack Down on Brand Name Drug Companies’ Egregious Pricing Practices OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE Lawmakers have an important opportunity this week to refocus attention on the urgent need for market-based solutions to hold Big Pharma accountable and lower prescription drug prices. On Wednesday, March 16, […]

ICYMI: HEALTH CARE LEADERS LAUNCH LOW-COST INSULIN INITIATIVE

03-7-2022 Blog Posts

Non-Profit and Private Sector Partners Work Together to Help Provide Relief from Big Pharma’s Insulin Price-Gouging Last week, non-profit Civica Rx and the organization’s private sector partners announced plans to manufacture and sell affordable insulin for no more than $30 per vial — demonstrating how health care leaders can work together to help deliver relief […]

ICYMI: NEW REPORT SHOWS REBATES NOT TIED TO LIST PRICE INCREASES

03-4-2022 Blog Posts

Matrix Global Advisors Report Further Undermines Big Pharma’s Supply Chain Blame Game A new report from Matrix Global Advisors (MGA), “Understanding Drug Rebates and Their Role in Promoting Competition,” finds price trends for rebated and non-rebated drugs were similar over the last four years – further undercutting the repeatedly debunked rhetoric from Big Pharma that […]

BIG PHARMA WATCH: STUDY FINDS DRUG COMPANIES HIKED PRICES FASTER THAN INFLATION ON 23 OF TOP 25 MOST POPULAR MEDICARE PART D DRUGS

02-28-2022 Blog Posts

KFF Analysis Shows Big Pharma’s Price Hikes Outpaced Inflation for Half of All Prescription Drugs Covered by Medicare A new analysis from the Kaiser Family Foundation (KFF) found Big Pharma hiked prices faster than the rate of inflation on 23 of the top 25 most popular prescription drugs in the Medicare Part D program in […]

BIG PHARMA EARNINGS WATCH: MERCK, ELI LILLY, AMGEN, PFIZER, GLAXOSMITHKLINE, ASTRAZENECA

02-18-2022 Blog Posts

New Earnings Reports Show Big Pharma Giants Continue to Reap Massive Profits, Beating Wall Street Expectations After Repeatedly Hiking Prices New earnings reports for the fourth quarter of 2021 demonstrate that the pharmaceutical industry continues to rake in massive profits after having hiked prices of prescription drugs repeatedly throughout the pandemic. Big Pharma giants Merck, […]

BIG PHARMA EARNINGS WATCH: ABBVIE, SANOFI, BRISTOL-MYERS SQUIBB, NOVARTIS

02-11-2022 Blog Posts

New Q4 Earnings Reports Underscore How Big Pharma’s Pandemic Price Hikes, Anti-Competitive Tactics Boost Profits Another round of fourth-quarter earnings reports from AbbVie, Sanofi, Bristol-Myers Squibb, and Novartis demonstrate that brand-name drug manufacturers continue to rake in blockbuster profits after hiking prices on multiple prescription drugs in their portfolios throughout the COVID-19 pandemic. All four […]

SECOND OPINION: PHRMA STUDY REHASHES DEBUNKED SUPPLY CHAIN BLAME GAMES

02-3-2022 Blog Posts

Big Pharma Sidesteps Industry’s Own Price Hikes and Egregious Practices in Latest Bid to Evade Accountability A recent Big Pharma study rehashes the tired tactic of blaming others in the supply chain for out-of-control prescription drug prices in a bid to evade accountability for the industry’s own egregious practices. The study, commissioned by the Pharmaceutical […]

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

01-28-2022 Blog Posts

J&J Surpasses Wall Street Expectations, Nearly Tripling Year-Over-Year Profits in Q4 After Hiking Prices on Dozens of Brand Name Drugs This week, Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the fourth quarter of 2021. As has become standard procedure for the Big Pharma giant, the company bested Wall […]

ICYMI: NEW REPORTS UNDERSCORE URGENCY FOR ACTION TO REIN IN BIG PHARMA’S OUT-OF-CONTROL DRUG PRICES

01-21-2022 Blog Posts

CBO Finds Net Prices for Brand Name Drugs More Than Doubled from 2009-2018; HHS Finds More Than Five Million Beneficiaries Struggled to Afford Prescriptions in 2019 Two government reports released this week underscore the urgency for action to rein in out-of-control prescription drug prices by holding Big Pharma accountable. A report released Wednesday from the […]

DOSE OF REALITY: NEW ANALYSIS UNDERSCORES HOW OFTEN BIG PHARMA’S PATENTS ARE UNRELATED TO CLINICAL INNOVATION

01-19-2022 Blog Posts

Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for Active Ingredients or New Molecules A new analysis published this week in Nature Biotechnology further reveals how the pharmaceutical industry’s abuse of the U.S. patent system prevents lower-cost alternatives from entering the market, limiting competition and driving increased spending for U.S. patients […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.